SG11201700476VA - Treatment of cancer using humanized anti-bcma chimeric antigen receptor - Google Patents

Treatment of cancer using humanized anti-bcma chimeric antigen receptor

Info

Publication number: SG11201700476VA
Authority: SG; Singapore
Prior art keywords: cancer; treatment; antigen receptor; chimeric antigen; humanized anti
Prior art date: 2014-07-21

Application number

SG11201700476VA

Inventor

Jennifer Brogdon

Eugene Choi

Hilmar Ebersbach

David Glass

Heather Huet

Carl H June

Joan Mannick

Michael C Milone

Leon Murphy

Gabriela Plesa

Celeste Richardson

Marco Ruella

Reshma Singh

Yongqiang Wang

Qilong Wu

Original Assignee

Novartis Ag

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-21

Filing date

2015-07-21

Publication date

2017-02-27

2015-07-21 Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag

2017-02-27 Publication of SG11201700476VA publication Critical patent/SG11201700476VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Oncology (AREA)
Mycology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11201700476VA 2014-07-21 2015-07-21 Treatment of cancer using humanized anti-bcma chimeric antigen receptor SG11201700476VA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN2014082586		2014-07-21
CN2014090501		2014-11-06
PCT/US2015/041378 WO2016014565A2 (en)	2014-07-21	2015-07-21	Treatment of cancer using humanized anti-bcma chimeric antigen receptor

Publications (1)

Publication Number	Publication Date
SG11201700476VA true SG11201700476VA (en)	2017-02-27

Family

ID=53901113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201700476VA SG11201700476VA (en)	2014-07-21	2015-07-21	Treatment of cancer using humanized anti-bcma chimeric antigen receptor

Country Status (16)

Country	Link
US (3)	US10174095B2 (en)
EP (1)	EP3172237A2 (en)
JP (2)	JP7054622B2 (en)
KR (1)	KR102612313B1 (en)
CN (1)	CN106687483B (en)
AU (2)	AU2015292744C1 (en)
BR (1)	BR112017001183A2 (en)
CA (1)	CA2955386A1 (en)
CO (1)	CO2017000507A2 (en)
IL (1)	IL250043B (en)
MX (1)	MX2017001011A (en)
MY (1)	MY181834A (en)
RU (1)	RU2751660C2 (en)
SG (1)	SG11201700476VA (en)
TW (1)	TWI750110B (en)
WO (1)	WO2016014565A2 (en)

Families Citing this family (346)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012333134B2 (en)	2011-07-22	2017-05-25	John Paul Guilinger	Evaluation and improvement of nuclease cleavage specificity
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
MY190711A (en)	2013-02-20	2022-05-12	Novartis Ag	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014145252A2 (en) *	2013-03-15	2014-09-18	Milone Michael C	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en)	2013-03-16	2019-03-21	諾華公司	Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
US20150044192A1 (en)	2013-08-09	2015-02-12	President And Fellows Of Harvard College	Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en)	2013-08-22	2016-06-07	President And Fellows Of Harvard College	Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en)	2013-09-06	2016-12-27	President And Fellows Of Harvard College	Delivery system for functional nucleases
US9388430B2 (en)	2013-09-06	2016-07-12	President And Fellows Of Harvard College	Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
EP3068435A1 (en)	2013-11-13	2016-09-21	Novartis AG	Mtor inhibitors for enhancing the immune response
US20150165054A1 (en)	2013-12-12	2015-06-18	President And Fellows Of Harvard College	Methods for correcting caspase-9 point mutations
WO2015090230A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en)	2013-12-20	2015-06-25	Novartis Ag	Regulatable chimeric antigen receptor
WO2015112626A1 (en) *	2014-01-21	2015-07-30	June Carl H	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SI3888674T1 (en)	2014-04-07	2024-08-30	Novartis Ag	Treatment of cancer using anti-cd19 chimeric antigen receptor
JP6698546B2 (en) *	2014-04-14	2020-05-27	セレクティスＣｅｌｌｅｃｔｉｓ	BCMA (CD269)-specific chimeric antigen receptor for cancer immunotherapy
US11041021B2 (en)	2014-05-23	2021-06-22	University Of Florida Research Foundation, Incorporated	Car based immunotherapy
LT3151672T (en)	2014-06-06	2021-02-10	Bluebird Bio, Inc.	Improved t cell compositions
TWI718992B (en)	2014-07-21	2021-02-21	瑞士商諾華公司	Treatment of cancer using a cll-1 chimeric antigen receptor
AU2015292744C1 (en)	2014-07-21	2021-01-21	Novartis Ag	Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
CN107109419B (en)	2014-07-21	2020-12-22	诺华股份有限公司	Treatment of cancer using CD33 chimeric antigen receptor
KR102523934B1 (en)	2014-07-24	2023-04-20	2세븐티 바이오, 인코포레이티드	Bcma chimeric antigen receptors
AU2015298571B2 (en)	2014-07-30	2020-09-03	President And Fellows Of Harvard College	Cas9 proteins including ligand-dependent inteins
TWI719946B (en)	2014-08-19	2021-03-01	瑞士商諾華公司	Treatment of cancer using a cd123 chimeric antigen receptor
EP3967709A1 (en)	2014-09-17	2022-03-16	Novartis AG	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN114107424A (en)	2014-10-08	2022-03-01	诺华股份有限公司	Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
JP7023708B2 (en) *	2014-11-12	2022-03-03	アロジーンセラピューティクス，インコーポレイテッド	Inhibitory chimeric antigen receptor
RS61781B1 (en)	2014-12-05	2021-06-30	Memorial Sloan Kettering Cancer Center	Antibodies targeting b-cell maturation antigen and methods of use
NZ732563A (en)	2014-12-05	2023-01-27	Memorial Sloan Kettering Cancer Center	Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SG10202013144UA (en)	2014-12-12	2021-02-25	Bluebird Bio Inc	Bcma chimeric antigen receptors
CA3197849A1 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
EP3250604B1 (en)	2015-01-26	2021-04-21	Cellectis	Mab-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
EP3256492A4 (en) *	2015-02-09	2018-07-11	University of Florida Research Foundation, Inc.	Bi-specific chimeric antigen receptor and uses thereof
US11248058B2 (en)	2015-02-19	2022-02-15	University Of Florida Research Foundation, Inc.	Chimeric antigen receptors and uses thereof
WO2016134371A2 (en)	2015-02-20	2016-08-25	Ohio State Innovation Foundation	Bivalent antibody directed against nkg2d and tumor associated antigens
BR112017018919A8 (en)	2015-03-05	2023-04-11	Hutchinson Fred Cancer Res	IMMUNOMODULATORY FUSION PROTEINS AND THEIR USES
US11045543B2 (en)	2015-04-06	2021-06-29	Cytoimmune Therapeutics, Inc.	EGFR-directed car therapy for glioblastoma
TWI746437B (en)	2015-04-08	2021-11-21	瑞士商諾華公司	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
WO2016166630A1 (en)	2015-04-13	2016-10-20	Pfizer Inc.	Chimeric antigen receptors targeting b-cell maturation antigen
CN118726268A (en)	2015-04-17	2024-10-01	诺华股份有限公司	Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells
US12128069B2 (en)	2015-04-23	2024-10-29	The Trustees Of The University Of Pennsylvania	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP2018515139A (en)	2015-05-08	2018-06-14	プレジデントアンドフェローズオブハーバードカレッジ	Universal donor stem cells and related methods
CN107995913B (en) *	2015-05-18	2022-02-11	T细胞受体治疗公司	Compositions and methods for reprogramming TCRs using fusion proteins
JP6857141B2 (en)	2015-05-20	2021-04-14	ノバルティスアーゲー	Pharmaceutical combination of everolimus and ductoric
CN111234027A (en)	2015-05-21	2020-06-05	哈普恩治疗公司	Trispecific binding proteins and methods of use
AU2016297014B2 (en)	2015-07-21	2021-06-17	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en)	2015-07-31	2015-09-16	King S College London	Therapeutic agents
EP3331913A1 (en)	2015-08-07	2018-06-13	Novartis AG	Treatment of cancer using chimeric cd3 receptor proteins
CN105384825B (en) *	2015-08-11	2018-06-01	南京传奇生物科技有限公司	A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
EP3344996A2 (en)	2015-09-03	2018-07-11	The Trustees Of The University Of Pennsylvania	Biomarkers predictive of cytokine release syndrome
GB201518816D0 (en)	2015-10-23	2015-12-09	Autolus Ltd	Receptor
IL310721A (en)	2015-10-23	2024-04-01	Harvard College	Nucleobase editors and uses thereof
AU2016353067B2 (en) *	2015-11-13	2023-10-05	Sanford Research	Anti-BCMA polypeptides and proteins
JP2018536436A (en)	2015-12-04	2018-12-13	ノバルティスアーゲー	Compositions and methods for immuno-oncology
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
WO2017112741A1 (en)	2015-12-22	2017-06-29	Novartis Ag	Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
US20190000880A1 (en)	2015-12-30	2019-01-03	Novartis Ag	Immune effector cell therapies with enhanced efficacy
WO2017130223A2 (en)	2016-01-29	2017-08-03	Virocan Therapeutics Pvt. Ltd.	A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
WO2017149515A1 (en)	2016-03-04	2017-09-08	Novartis Ag	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CA3015237A1 (en) *	2016-03-17	2017-09-21	The University Of British Columbia	Devices and methods for cellular secretion analysis
EP3432924A1 (en)	2016-03-23	2019-01-30	Novartis AG	Cell secreted minibodies and uses thereof
TW202423985A (en) *	2016-03-31	2024-06-16	美商恩格姆生物製藥公司	Binding proteins and methods of use thereof
EA201891966A1 (en) *	2016-04-01	2019-04-30	Кайт Фарма, Инк.	MOLECULES ASSOCIATING BCMA AND METHODS OF THEIR APPLICATION
KR102608405B1 (en)	2016-04-01	2023-12-01	카이트 파마 인코포레이티드	Chimeric receptors and methods of use thereof
PE20190173A1 (en)	2016-04-01	2019-02-01	Kite Pharma Inc	CHEMERIC ANTIGEN RECEPTORS AND T-CELLS AND METHODS OF USE
EP3443001A4 (en)	2016-04-11	2020-04-29	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
US10188749B2 (en)	2016-04-14	2019-01-29	Fred Hutchinson Cancer Research Center	Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017181119A2 (en) *	2016-04-15	2017-10-19	Novartis Ag	Compositions and methods for selective protein expression
WO2017190096A1 (en)	2016-04-29	2017-11-02	University Of Florida Research Foundation Incorporated	Chimeric antigen receptors and uses thereof
MA45025A (en)	2016-05-20	2019-03-27	Lilly Co Eli	COMBINATION TREATMENT USING NOTCH AND PD-1 OR PD-L1 INHIBITORS
CN105837693A (en) *	2016-05-30	2016-08-10	李斯文	BCMA-based (B cell maturation antigen-based) chimeric antigen receptor and preparation method and application thereof
WO2017210617A2 (en)	2016-06-02	2017-12-07	Porter, David, L.	Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3026778A1 (en) *	2016-06-07	2017-12-14	Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft	Chimeric antigen receptor and car-t cells that bind bcma
CA3029209A1 (en) *	2016-06-21	2017-12-28	Teneobio, Inc.	Cd3 binding antibodies
CN107586342A (en) *	2016-07-08	2018-01-16	生命序有限公司	Recombinant immune checkpoint acceptor and its application
CN107586341A (en) *	2016-07-08	2018-01-16	生命序有限公司	Recombinant immune checkpoint acceptor and immunologic test point suppress coexpression and the application of molecule
US20190336504A1 (en)	2016-07-15	2019-11-07	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
KR102565885B1 (en) *	2016-07-20	2023-08-09	유니버시티 오브 유타 리서치 파운데이션	CD229 CAR T Cells and Methods of Using The Same
CA3031846A1 (en) *	2016-07-26	2018-02-01	Tessa Therapeutics Pte. Ltd.	Chimeric antigen receptor
SG11201900677SA (en)	2016-07-28	2019-02-27	Novartis Ag	Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
US20190161542A1 (en)	2016-08-01	2019-05-30	Novartis Ag	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US11242376B2 (en)	2016-08-02	2022-02-08	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
IL308426A (en)	2016-08-03	2024-01-01	Harvard College	Adenosine nucleobase editors and uses thereof
WO2018027135A1 (en) *	2016-08-04	2018-02-08	Unum Therapeutics Inc.	Treatment of lymphoma using antibody-coupled t cell receptor
CA3033327A1 (en)	2016-08-09	2018-02-15	President And Fellows Of Harvard College	Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en)	2016-08-24	2023-01-03	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
PL4050034T3 (en)	2016-09-14	2024-07-22	Teneoone, Inc.	Cd3 binding antibodies
MA46236A (en) *	2016-09-14	2019-07-24	Janssen Biotech Inc	CHEMERICAL ANTIGENIC RECEPTORS INCLUDING AREAS OF FIBRONECTIN TYPE III SPECIFIC TO BCMA, AND CORRESPONDING USES
WO2018057585A1 (en) *	2016-09-21	2018-03-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
JP6866475B2 (en) *	2016-09-23	2021-04-28	フレッドハッチンソンキャンサーリサーチセンター	Minor histocompatibility (H) TCR specific for antigen HA-1 and its use
EP3519577A1 (en)	2016-09-28	2019-08-07	Novartis AG	Porous membrane-based macromolecule delivery system
JP2019532953A (en) *	2016-09-30	2019-11-14	ノバルティスアーゲー	Immune effector cell therapy with enhanced efficacy
EP3445787B1 (en)	2016-10-07	2020-12-02	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3039646A1 (en)	2016-10-07	2018-04-12	Novartis Ag	Chimeric antigen receptors for the treatment of cancer
CA3039774A1 (en) *	2016-10-10	2018-04-19	The National Institute for Biotechnology in the Negev Ltd.	Non-cytotoxic modified cells and use thereof
CN107936120B (en) *	2016-10-13	2021-03-09	上海赛比曼生物科技有限公司	CD19 targeted chimeric antigen receptor and preparation method and application thereof
AU2017342543B2 (en)	2016-10-14	2024-06-27	President And Fellows Of Harvard College	AAV delivery of nucleobase editors
WO2018083204A1 (en)	2016-11-02	2018-05-11	Engmab Sàrl	Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
BR112019009099A2 (en)	2016-11-04	2019-07-16	Bluebird Bio Inc	anti-bcma t cell compositions
WO2018098365A2 (en)	2016-11-22	2018-05-31	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
KR20190089005A (en)	2016-11-23	2019-07-29	노파르티스 아게	Methods of enhancing the immune response using everolimus, doxorubicin, or both
JP2019536786A (en) *	2016-11-30	2019-12-19	イントレキソンコーポレーション	Steroid administration and immunotherapy
CN110662552A (en) *	2016-11-30	2020-01-07	昂科梅德制药有限公司	Methods of cancer treatment comprising TIGIT binding agents
CN107058315B (en) *	2016-12-08	2019-11-08	上海优卡迪生物医药科技有限公司	Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application
EP3559035A1 (en)	2016-12-21	2019-10-30	TeneoBio, Inc.	Anti-bcma heavy chain-only antibodies
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
JP7348063B2 (en)	2017-01-05	2023-09-20	フレッドハッチンソンキャンサーセンター	Systems and methods for improving vaccine efficacy
WO2018132506A1 (en) *	2017-01-10	2018-07-19	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
JP7280828B2 (en) *	2017-01-23	2023-05-24	クレージュメディカルカンパニー，リミテッド	Antibodies targeting BCMA and uses thereof
ES2912408T3 (en)	2017-01-26	2022-05-25	Novartis Ag	CD28 compositions and methods for therapy with chimeric receptors for antigens
WO2018144535A1 (en)	2017-01-31	2018-08-09	Novartis Ag	Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
AU2018219226A1 (en)	2017-02-07	2019-08-15	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
AU2018219348A1 (en) *	2017-02-10	2019-08-29	Dragonfly Therapeutics, Inc.	Proteins binding BCMA, NKG2D and CD16
EP4269594A3 (en)	2017-02-17	2023-12-20	Fred Hutchinson Cancer Center	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3589295B1 (en)	2017-02-28	2024-09-11	Endocyte, Inc.	Compositions and methods for car t cell therapy
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
JP2020510439A (en)	2017-03-10	2020-04-09	プレジデントアンドフェローズオブハーバードカレッジ	Base-editing factor from cytosine to guanine
AU2018236450A1 (en)	2017-03-16	2019-10-03	The General Hospital Corporation	Chimeric antigen receptors targeting CD37
WO2018170475A1 (en)	2017-03-17	2018-09-20	Fred Hutchinson Cancer Research Center	Immunomodulatory fusion proteins and uses thereof
KR20190130608A (en) *	2017-03-22	2019-11-22	노파르티스 아게	Compositions and Methods for Immune Oncology
IL306092A (en)	2017-03-23	2023-11-01	Harvard College	Nucleobase editors comprising nucleic acid programmable dna binding proteins
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
US11560566B2 (en)	2017-05-12	2023-01-24	President And Fellows Of Harvard College	Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019097305A2 (en)	2017-05-12	2019-05-23	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2020522489A (en) *	2017-06-02	2020-07-30	ジュノーセラピューティクスインコーポレイテッド	Articles of manufacture and methods for treatment with adoptive cell therapy
WO2018232195A1 (en)	2017-06-14	2018-12-20	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
CN117567624A (en)	2017-06-20	2024-02-20	特纳奥尼股份有限公司	Heavy chain-only anti-BCMA antibodies
EP3642237A2 (en)	2017-06-20	2020-04-29	Teneobio, Inc.	Anti-bcma heavy chain-only antibodies
SG11202000555UA (en) *	2017-06-21	2020-02-27	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars), compositions and methods thereof
AU2018289428B2 (en) *	2017-06-21	2024-06-27	The General Hospital Corporation	Methods and compositions for chimeric antigen receptor targeting cancer cells
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
MX2019015885A (en)	2017-06-22	2020-09-10	Novartis Ag	Antibody molecules to cd73 and uses thereof.
CN107267619A (en) *	2017-07-04	2017-10-20	武汉波睿达生物科技有限公司	The fluorescence quantitative kit that CAR is expressed in a kind of CART cells for detecting targeting CD33
KR20200027508A (en) *	2017-07-07	2020-03-12	에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨	Chimeric antigen receptor with mutated CD28 costimulatory domain
WO2019014581A1 (en)	2017-07-14	2019-01-17	The Broad Institute, Inc.	Methods and compositions for modulating cytotoxic lymphocyte activity
CN111801345A (en)	2017-07-28	2020-10-20	哈佛大学的校长及成员们	Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
WO2019045086A1 (en) *	2017-08-29	2019-03-07	林化成株式会社	USE FOR SPECIFIC ANTIBODY FOR ACTIVE OR LATENT TGF-β1
WO2019139645A2 (en)	2017-08-30	2019-07-18	President And Fellows Of Harvard College	High efficiency base editors comprising gam
CA3075716A1 (en)	2017-09-14	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
CA3075714A1 (en)	2017-09-14	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
CN111094353A (en)	2017-09-14	2020-05-01	葛兰素史密斯克莱知识产权发展有限公司	Combination therapy for cancer
CA3076972C (en) *	2017-09-29	2023-09-26	Mogam Institute For Biomedical Research	Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
EP3687569A1 (en)	2017-09-29	2020-08-05	Cell Design Labs, Inc.	Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
BR112020006643A2 (en)	2017-10-03	2020-09-24	Juno Therapeutics Inc	hpv-specific binding molecules
KR20220111743A (en)	2017-10-13	2022-08-09	하푼 테라퓨틱스, 인크.	B cell maturation antigen binding proteins
AU2018352592A1 (en)	2017-10-16	2020-06-04	Beam Therapeutics, Inc.	Uses of adenosine base editors
SG11202003415XA (en)	2017-10-18	2020-05-28	Novartis Ag	Compositions and methods for selective protein degradation
MX2020004229A (en)	2017-10-25	2020-07-22	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells.
AU2018358067A1 (en)	2017-11-01	2020-05-07	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
JP7447006B2 (en)	2017-11-01	2024-03-11	ジュノーセラピューティクスインコーポレイテッド	Chimeric antigen receptor specific for B cell maturation antigen (BCMA)
US12031975B2 (en)	2017-11-01	2024-07-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
WO2019089982A1 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
CN109748968B (en) *	2017-11-03	2020-12-01	西安宇繁生物科技有限责任公司	BCMA specific chimeric antigen receptor T cell and application thereof
AU2018359907A1 (en)	2017-11-06	2020-05-07	Fred Hutchinson Cancer Center	Combination of a cell therapy and a gamma secretase inhibitor
US12018080B2 (en)	2017-11-13	2024-06-25	The Broad Institute, Inc.	Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
US20200360431A1 (en) *	2017-11-15	2020-11-19	Novartis Ag	Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
EP3710471A1 (en)	2017-11-16	2020-09-23	Kite Pharma, Inc.	Modified chimeric antigen receptors and methods of use
EP3717907A1 (en) *	2017-11-30	2020-10-07	Novartis AG	Bcma-targeting chimeric antigen receptor, and uses thereof
US20200332255A1 (en) *	2017-12-13	2020-10-22	Janssen Biotech, Inc.	Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
US20210139557A1 (en) *	2017-12-20	2021-05-13	Poseida Therapeutics, Inc.	Vcar compositions and methods for use
EP3729081A1 (en) *	2017-12-21	2020-10-28	F. Hoffmann-La Roche AG	Car-t cell assay for specificity test of novel antigen binding moieties
SG11202005880XA (en)	2017-12-22	2020-07-29	Teneobio Inc	Heavy chain antibodies binding to cd22
CN109971715A (en) *	2017-12-28	2019-07-05	深圳华大生命科学研究院	A kind of cultural method of specific amplification CAR-T cell
EP3737408A1 (en)	2018-01-08	2020-11-18	Novartis AG	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN112055595A (en)	2018-01-22	2020-12-08	恩多塞特公司	Methods of use of CAR T cells
CN108314738B (en) *	2018-01-29	2020-09-08	山东兴瑞生物科技有限公司	Bispecific chimeric antigen receptor co-expressing cytokine IL-21, plasmid, CIK cell and MM disease application
WO2019152660A1 (en)	2018-01-31	2019-08-08	Novartis Ag	Combination therapy using a chimeric antigen receptor
TWI800854B (en) *	2018-02-01	2023-05-01	大陸商信達生物製藥（蘇州）有限公司	Full-human anti-b cell mature antigen (bcma) single chain antibody and use thereof
US11266690B2 (en)	2018-02-01	2022-03-08	Nanjing Iaso Biotherapeutics Co., Ltd.	Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
TWI728308B (en) *	2018-02-01	2021-05-21	大陸商南京馴鹿醫療技術有限公司	A chimeric antigen receptor (car) binding to bcma and use thereof
WO2019160956A1 (en)	2018-02-13	2019-08-22	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019157691A1 (en) *	2018-02-14	2019-08-22	宜明细胞生物科技有限公司	Recombinant chimeric antigen receptor gene and use thereof
WO2019164891A1 (en) *	2018-02-21	2019-08-29	Celgene Corporation	Bcma-binding antibodies and uses thereof
JP2021514662A (en) *	2018-03-08	2021-06-17	フェインズセラピューティクス，インコーポレーテッド	Anti-TIP-1 antibody and its use
BR112020018301A2 (en) *	2018-03-16	2020-12-22	Cytoimmune Therapeutics, Inc.	IMMUNOTHERAPY WITH BISPECIFIC ANTIBODY CAR CELLS
WO2019200214A1 (en)	2018-04-13	2019-10-17	The Regents Of The University Of Michigan	Compositions and methods for treating cancer
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
AU2019260717A1 (en) *	2018-04-27	2020-11-12	Novartis Ag	Dosing of a bispecific antibody that bind CD123 and CD3
EP3784351A1 (en)	2018-04-27	2021-03-03	Novartis AG	Car t cell therapies with enhanced efficacy
SG11202010676TA (en) *	2018-04-28	2020-11-27	Immunotech Biopharm Co Ltd	Improved t-cell therapy
EP3788369A1 (en)	2018-05-01	2021-03-10	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019266398A1 (en)	2018-05-11	2020-11-19	Crispr Therapeutics Ag	Methods and compositions for treating cancer
US20210198342A1 (en) *	2018-05-22	2021-07-01	Nantkwest, Inc.	FC-EPSILON CAR (Very imp commercially - in clinical trial)
US20210213063A1 (en)	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
TW202015726A (en)	2018-05-30	2020-05-01	瑞士商諾華公司	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
US20210371932A1 (en)	2018-06-01	2021-12-02	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
JP2021525509A (en) *	2018-06-01	2021-09-27	ユニバーシティオブサザンカリフォルニア	Diverse antigen-binding domains for cell therapy, new platforms and other enhancements
SG11202010579XA (en)	2018-06-01	2020-12-30	Novartis Ag	Binding molecules against bcma and uses thereof
CA3101641A1 (en) *	2018-06-04	2019-12-12	Intrexon Corporation	Muc16 specific chimeric antigen receptors and uses thereof
CN112423793A (en)	2018-06-05	2021-02-26	宾夕法尼亚大学董事会	Compositions and methods for muscle specific kinase chimeric autoantibody receptor cells
WO2019237035A1 (en)	2018-06-08	2019-12-12	Intellia Therapeutics, Inc.	Compositions and methods for immunooncology
US20220403001A1 (en)	2018-06-12	2022-12-22	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3806871A4 (en)	2018-06-12	2022-02-23	The Regents of the University of California	Single-chain bispecific chimeric antigen receptors for the treatment of cancer
TW202016139A (en) *	2018-06-13	2020-05-01	瑞士商諾華公司	Bcma chimeric antigen receptors and uses thereof
US12036240B2 (en)	2018-06-14	2024-07-16	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210261689A1 (en) *	2018-06-14	2021-08-26	Bluebird Bio, Inc.	Anti-bcma car antibodies, conjugates, and methods of use
AR116109A1 (en)	2018-07-10	2021-03-31	Novartis Ag	DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CA3107383A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN112930199B (en) *	2018-07-24	2024-08-13	恺兴生命科技(上海)有限公司	Method for treating tumor by immune effector cells
CN110850067B (en) *	2018-08-21	2023-08-15	上海恒润达生生物科技股份有限公司	Chimeric antigen receptor affinity detection method
CN109134665B (en) *	2018-08-24	2021-06-11	上海先博生物科技有限公司	BCMA chimeric antigen receptor based on single domain antibody and application
EA202190608A1 (en) *	2018-08-24	2021-06-01	Шэньчжэнь Преджин Байофарма Ко., Лтд.	SINGLE DOMAIN ANTI-BCMA ANTIBODIES AND THEIR APPLICATION
AU2019331496A1 (en)	2018-08-31	2021-03-18	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
KR20210073520A (en) *	2018-09-05	2021-06-21	포세이다 테라퓨틱스, 인크.	Allogeneic cell compositions and methods of use thereof
CN111019905A (en) *	2018-09-12	2020-04-17	上海斯丹赛生物技术有限公司	CAR modified cell and application thereof in preparation of autoimmune disease drugs
EP3853254A1 (en)	2018-09-20	2021-07-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd123 immunotherapy
CN112805371A (en) *	2018-09-21	2021-05-14	佧珐药业有限公司	Method for carrying out gene editing on cells based on CRISPR/Cas system
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
SG11202102781UA (en) *	2018-09-27	2021-04-29	Autolus Ltd	Chimeric antigen receptor
KR20210070330A (en) *	2018-10-01	2021-06-14	아디셋 바이오, 인크.	Compositions and methods relating to engineered and non-engineered γδ-T cells for the treatment of hematologic tumors
WO2020072700A1 (en)	2018-10-02	2020-04-09	Dana-Farber Cancer Institute, Inc.	Hla single allele lines
JP7126624B2 (en) *	2018-10-10	2022-08-26	深▲せん▼華大生命科学研究院	ANTI-BCMA SINGLE-CHAIN ANTIBODY SCFV, AND METHOD FOR PRODUCING THEREOF AND USE THEREOF
WO2020081730A2 (en)	2018-10-16	2020-04-23	Massachusetts Institute Of Technology	Methods and compositions for modulating microenvironment
US20210386788A1 (en)	2018-10-24	2021-12-16	Obsidian Therapeutics, Inc.	Er tunable protein regulation
US20220170097A1 (en)	2018-10-29	2022-06-02	The Broad Institute, Inc.	Car t cell transcriptional atlas
WO2020089794A1 (en)	2018-10-31	2020-05-07	Glaxosmithkline Intellectual Property Development Limited	Methods of treating cancer
BR112021007626A2 (en)	2018-11-01	2021-10-13	Juno Therapeutics, Inc.	CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G-PROTEIN-COUPLED RECEPTOR CLASS C, GROUP 5, MEMBER D RECEPTOR (GPRC5D)
KR20210113169A (en) *	2018-11-01	2021-09-15	주노 쎄러퓨티크스 인코퍼레이티드	Treatment method using chimeric antigen receptor specific for Β cell maturation antigen
KR20210090220A (en) *	2018-11-06	2021-07-19	워싱턴 유니버시티	Chimeric Antigen Receptor Memory-Like (CARML) NK Cells and Methods of Making and Using the Same
WO2020123716A1 (en)	2018-12-11	2020-06-18	Obsidian Therapeutics, Inc.	Membrane bound il12 compositions and methods for tunable regulation
WO2020131586A2 (en)	2018-12-17	2020-06-25	The Broad Institute, Inc.	Methods for identifying neoantigens
CN113271945A (en)	2018-12-20	2021-08-17	诺华股份有限公司	Dosing regimens and pharmaceutical combinations comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives
CN109485734B (en) *	2018-12-30	2020-05-12	广州百暨基因科技有限公司	Bispecific chimeric antigen receptor targeting BCMA and CD19 and application thereof
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
SI3749338T1 (en)	2019-01-16	2024-09-30	Caribou Biosciences, Inc.	Humanized bcma antibody and bcma-car-t cells
CN111454358A (en) *	2019-01-18	2020-07-28	四川科伦博泰生物医药股份有限公司	Chimeric antigen receptor and application thereof
WO2020165834A1 (en)	2019-02-15	2020-08-20	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220144807A1 (en)	2019-02-15	2022-05-12	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
MX2021010150A (en)	2019-02-25	2021-09-14	Novartis Ag	Mesoporous silica particles compositions for viral delivery.
JP2022524081A (en)	2019-03-08	2022-04-27	オブシディアンセラピューティクス，インコーポレイテッド	Human Carbonic Amhydrase 2 Compositions and Methods for Adjustable Control
US20220154282A1 (en)	2019-03-12	2022-05-19	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
KR102588292B1 (en) *	2019-03-15	2023-10-11	카티전 테라퓨틱스, 인코포레이티드	anti-BCMA chimeric antigen receptor
EP3942023A1 (en)	2019-03-18	2022-01-26	The Broad Institute, Inc.	Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020242032A1 (en)	2019-03-19	2021-10-07	Massachusetts Institute Of Technology	Methods and compositions for editing nucleotide sequences
EP3942025A1 (en)	2019-03-21	2022-01-26	Novartis AG	Car-t cell therapies with enhanced efficacy
EP3953455A1 (en)	2019-04-12	2022-02-16	Novartis AG	Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en)	2019-04-24	2022-03-02	Novartis AG	Compositions and methods for selective protein degradation
CN113939319A (en)	2019-04-30	2022-01-14	克里斯珀医疗股份公司	Allogeneic cell therapy of genetically engineered T cells targeting CD19 against B cell malignancies
EP3733707A1 (en) *	2019-04-30	2020-11-04	Celyad S.A.	Car t-cells targeting bcma and uses thereof
WO2020224605A1 (en) *	2019-05-07	2020-11-12	亘喜生物科技（上海）有限公司	Bcma-targeting engineered immune cell and use thereof
EP3967329A4 (en)	2019-05-07	2023-06-14	Gracell Biotechnologies (Shanghai) Co., Ltd.	Engineered immune cell targeting bcma and use thereof
WO2020236967A1 (en)	2019-05-20	2020-11-26	The Broad Institute, Inc.	Random crispr-cas deletion mutant
CA3140668A1 (en)	2019-06-12	2020-12-17	Obsidian Therapeutics, Inc.	Ca2 compositions and methods for tunable regulation
EP3983537A1 (en)	2019-06-12	2022-04-20	Obsidian Therapeutics, Inc.	Ca2 compositions and methods for tunable regulation
AU2020291938A1 (en)	2019-06-14	2022-01-20	Teneobio, Inc.	Multispecific heavy chain antibodies binding to CD22 and CD3
KR20220038362A (en)	2019-07-02	2022-03-28	프레드 헛친슨 켄서 리서치 센터	Recombinant AD35 Vector and Related Gene Therapy Improvements
CN112300997A (en) *	2019-08-01	2021-02-02	上海赛比曼生物科技有限公司	Universal CAR-T cell and preparation and application thereof
WO2021024133A2 (en)	2019-08-06	2021-02-11	Glaxosmithkline Intellectual Property Development Limited	Biopharmacuetical compositions and related methods
US20220282333A1 (en)	2019-08-13	2022-09-08	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
CN112409482B (en) *	2019-08-20	2022-08-26	杭州尚健生物技术有限公司	BCMA antibodies
US20220298501A1 (en)	2019-08-30	2022-09-22	The Broad Institute, Inc.	Crispr-associated mu transposase systems
GB2628935A (en)	2019-09-03	2024-10-09	Myeloid Therapeutics Inc	Methods and compositions for genomic integration
WO2021046205A1 (en) *	2019-09-04	2021-03-11	Tmunity Therapeutics Inc.	Adoptive cell therapy and methods of dosing thereof
US20220348937A1 (en)	2019-09-06	2022-11-03	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
EP4031578A1 (en)	2019-09-18	2022-07-27	Novartis AG	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en)	2019-10-30	2023-12-19	Massachusetts Institute Of Technology	Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
JP2023506130A (en) *	2019-11-05	2023-02-15	ロンザウォーカーズヴィル，インコーポレーテッド	Allogeneic T cells and method for producing same
WO2021108613A1 (en)	2019-11-26	2021-06-03	Novartis Ag	Cd19 and cd22 chimeric antigen receptors and uses thereof
AR120566A1 (en)	2019-11-26	2022-02-23	Novartis Ag	CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
EP4065137A1 (en)	2019-11-28	2022-10-05	Glycostem Therapeutics B.V.	Method for obtaining car-nk cells
BR112022011902A2 (en)	2019-12-20	2022-09-06	Novartis Ag	COMBINATION THERAPIES
KR20220128650A (en) *	2020-01-13	2022-09-21	엔카르타, 인크.	BCMA-Induced Cell Immunotherapy Compositions and Methods
US20230076768A1 (en)	2020-01-14	2023-03-09	Synthekine, Inc.	IL2 Orthologs and Methods of Use
WO2021173985A2 (en)	2020-02-27	2021-09-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
US20230174933A1 (en)	2020-02-27	2023-06-08	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
KR102371151B1 (en) *	2020-03-13	2022-03-07	주식회사 큐로셀	Anti-bcma-binding domains, fusion proteins comprising thereof, and compositions comprising thereof
CN112851815B (en) *	2020-03-17	2023-08-08	西安宇繁生物科技有限责任公司	anti-BCMA antibody or antigen binding fragment thereof, and preparation method and application thereof
WO2021202798A1 (en) *	2020-04-02	2021-10-07	The United States Of America As Represented By The Secretary Of The Navy	Antigen binding proteins to class 5 etec adhesins
CN111484561A (en) *	2020-04-07	2020-08-04	北京荣瑷医学生物科技有限责任公司	Chimeric antigen receptor targeting CD19 molecule
IL297147A (en)	2020-04-10	2022-12-01	Juno Therapeutics Inc	Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
MX2022013530A (en)	2020-04-28	2023-02-01	Juno Therapeutics Inc	Combination of bcma-directed t cell therapy and an immunomodulatory compound.
AU2021263448A1 (en)	2020-04-29	2022-11-24	Teneobio, Inc.	Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4146706A4 (en) *	2020-05-04	2024-05-29	The Regents of the University of California	Inhibiting anti-enpp1 antibodies
IL297761A (en)	2020-05-08	2022-12-01	Broad Inst Inc	Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4165169A1 (en)	2020-06-11	2023-04-19	Novartis AG	Zbtb32 inhibitors and uses thereof
KR102316091B1 (en) *	2020-06-17	2021-10-25	국립암센터	Chimeric antigen receptor targeting BCMA and use thereof
KR20230027056A (en)	2020-06-23	2023-02-27	노파르티스 아게	Dosage regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en)	2020-08-03	2023-06-07	Novartis AG	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023538118A (en)	2020-08-21	2023-09-06	ノバルティスアーゲー	Compositions and methods for in vivo generation of CAR-expressing cells
WO2022060806A1 (en)	2020-09-16	2022-03-24	Obsidian Therapeutics, Inc.	Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
AU2021378316A1 (en)	2020-11-13	2023-06-01	Novartis Ag	Combination therapies with chimeric antigen receptor (car)-expressing cells
AR124414A1 (en)	2020-12-18	2023-03-22	Century Therapeutics Inc	CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY
EP4263590A1 (en)	2020-12-21	2023-10-25	Allogene Therapeutics, Inc.	Protease-activating cd45-gate car
CN113087798B (en) *	2020-12-31	2022-05-24	北京艺妙神州医药科技有限公司	anti-BCMA antibody and application thereof
KR20230142470A (en)	2021-01-29	2023-10-11	알로젠 테라퓨틱스 인코포레이티드	Knockdown or knockout of one or more of TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, and RFXANK to mitigate T cell recognition of allogeneic cell products
WO2022178367A2 (en) *	2021-02-19	2022-08-25	University Of Southern California	Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
TW202304979A (en)	2021-04-07	2023-02-01	瑞士商諾華公司	USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
KR20220144000A (en)	2021-04-16	2022-10-26	주식회사 이뮤노로지컬디자이닝랩	Chimeric antigen receptor specifically binding to programmed death-ligand 1(PD-L1) and use thereof
KR20230171468A (en)	2021-04-16	2023-12-20	셀진 코포레이션	Combination therapy with BCMA-directed T cell therapy
CN117529333A (en)	2021-04-16	2024-02-06	细胞基因公司	T cell therapy for patients previously undergoing stem cell transplantation
CA3218362A1 (en)	2021-04-27	2022-11-03	Novartis Ag	Viral vector production system
JP2024517863A (en)	2021-05-06	2024-04-23	ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Methods for stimulating and transducing cells
US20240360181A1 (en) *	2021-05-20	2024-10-31	Achelois Biopharma, Inc.	Compositions and methods for multivalent surface display on enveloped particles
KR20220157686A (en) *	2021-05-21	2022-11-29	주식회사 지놈앤컴퍼니	Anti-bcam antibody or antigen-binding fragment thereof
CN117396513A (en)	2021-05-28	2024-01-12	葛兰素史密斯克莱知识产权发展有限公司	Combination therapy for the treatment of cancer
US20240316103A1 (en) *	2021-06-28	2024-09-26	Meridian Therapeutics, Inc.	Compositions and methods of treating plasma cell disorders including multiple myeloma with a vaccine composition and myeloma-specific car-t cells
CA3227515A1 (en)	2021-08-03	2023-02-09	Glaxosmithkline Intellectual Property Development Limited	Biopharmaceutical compositions and stable isotope labeling peptide mapping method
AU2022326565A1 (en)	2021-08-11	2024-02-08	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy
WO2023019229A1 (en)	2021-08-11	2023-02-16	Sana Biotechnology, Inc.	Genetically modified primary cells for allogeneic cell therapy
WO2023019225A2 (en)	2021-08-11	2023-02-16	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
EP4384598A1 (en)	2021-08-11	2024-06-19	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
EP4388000A1 (en)	2021-08-20	2024-06-26	Novartis AG	Methods of making chimeric antigen receptor?expressing cells
WO2023030393A1 (en) *	2021-09-01	2023-03-09	中国科学院生物物理研究所	Chimeric antigen receptor and use thereof
WO2023035001A1 (en) *	2021-09-03	2023-03-09	Angarus Therapeutics, Inc.	Enpp1 inhibitors and immune cells expressing chimeric antigen receptors
EP4412713A1 (en)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Combination therapies for treating cancer
KR20240112994A (en)	2021-11-03	2024-07-19	셀진 코포레이션	Chimeric antigen receptor specific for B-cell maturation antigen for use in treating myeloma
EP4428156A1 (en) *	2021-12-03	2024-09-11	Shandong Simcere Biopharmaceutical Co., Ltd.	Anti-bcma nanobody and use thereof
CN118401561A (en) *	2021-12-16	2024-07-26	浙江瑞加美生物科技有限公司	Humanized BCMA antibodies and BCMA-CAR-T/BCMA-CAR-DNT cells
CA3241997A1 (en)	2021-12-21	2023-06-29	Taochao TAN	Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof
CN118591560A (en)	2022-01-25	2024-09-03	葛兰素史密斯克莱知识产权发展有限公司	Combination therapy for cancer
WO2023147515A1 (en)	2022-01-28	2023-08-03	Juno Therapeutics, Inc.	Methods of manufacturing cellular compositions
AU2023220128A1 (en)	2022-02-17	2024-08-22	Sana Biotechnology, Inc.	Engineered cd47 proteins and uses thereof
US11590169B1 (en)	2022-03-02	2023-02-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2023214325A1 (en)	2022-05-05	2023-11-09	Novartis Ag	Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023213969A1 (en)	2022-05-05	2023-11-09	Juno Therapeutics Gmbh	Viral-binding protein and related reagents, articles, and methods of use
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en)	2022-05-11	2023-11-16	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Methods of manufacturing t cell therapies
WO2023230548A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Method for predicting response to a t cell therapy
CN114805584B (en) *	2022-06-30	2022-09-09	上海优替济生生物医药有限公司	Antigen binding proteins and uses thereof
US20240042030A1 (en)	2022-07-29	2024-02-08	Allogene Therapeutics, Inc.	Engineered cells with reduced gene expression to mitigate immune cell recognition
US20240041929A1 (en)	2022-08-05	2024-02-08	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for gprc5d and bcma
WO2024077256A1 (en)	2022-10-07	2024-04-11	The General Hospital Corporation	Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024089639A1 (en)	2022-10-26	2024-05-02	Novartis Ag	Lentiviral formulations
WO2024097314A2 (en)	2022-11-02	2024-05-10	Sana Biotechnology, Inc.	Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024100604A1 (en)	2022-11-09	2024-05-16	Juno Therapeutics Gmbh	Methods for manufacturing engineered immune cells
WO2024102954A1 (en)	2022-11-10	2024-05-16	Massachusetts Institute Of Technology	Activation induced clipping system (aics)
WO2024107014A1 (en) *	2022-11-18	2024-05-23	Genome And Company	Anti-basal cell adhesion molecule antibody-drug conjugate
WO2024121711A1 (en)	2022-12-05	2024-06-13	Glaxosmithkline Intellectual Property Development Limited	Methods of treatment using b-cell maturation antigen antagonists
WO2024124044A1 (en)	2022-12-07	2024-06-13	The Brigham And Women’S Hospital, Inc.	Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024152529A1 (en) *	2023-01-18	2024-07-25	成都地奥制药集团有限公司	Human anti-human pla2r antibody standard substance and use thereof
WO2024161021A1 (en)	2023-02-03	2024-08-08	Juno Therapeutics Gmbh	Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en)	2023-02-10	2024-08-15	Celgene Corporation	Assessment of bcma in biological samples
CN116854825B (en) *	2023-06-29	2024-03-01	徐州医科大学	Humanized chimeric antigen receptor targeting BCMA and uses thereof
CN118393137B (en) *	2024-07-01	2024-08-20	广东赛尔生物科技有限公司	Detection kit for intestinal tract protective bacteria and application thereof

Family Cites Families (373)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4433059A (en)	1981-09-08	1984-02-21	Ortho Diagnostic Systems Inc.	Double antibody conjugate
US4444878A (en)	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
DE3381783D1 (en)	1982-03-03	1990-09-13	Genentech Inc	HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5869620A (en)	1986-09-02	1999-02-09	Enzon, Inc.	Multivalent antigen-binding proteins
US5906936A (en)	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
JPH021556A (en)	1988-06-09	1990-01-05	Snow Brand Milk Prod Co Ltd	Hybrid antibody and production thereof
US6303121B1 (en)	1992-07-30	2001-10-16	Advanced Research And Technology	Method of using human receptor protein 4-1BB
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
WO1991003493A1 (en)	1989-08-29	1991-03-21	The University Of Southampton	Bi-or trispecific (fab)3 or (fab)4 conjugates
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5273743A (en)	1990-03-09	1993-12-28	Hybritech Incorporated	Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en)	1990-06-11	1990-08-01	Celltech Ltd	Multivalent antigen-binding proteins
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
AU643109B2 (en)	1990-12-14	1993-11-04	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
IE920716A1 (en)	1991-03-07	1992-09-09	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
DE4118120A1 (en)	1991-06-03	1992-12-10	Behringwerke Ag	TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
US6511663B1 (en)	1991-06-11	2003-01-28	Celltech R&D Limited	Tri- and tetra-valent monospecific antigen-binding proteins
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2136092T3 (en)	1991-09-23	1999-11-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
AU676150B2 (en)	1992-01-23	1997-03-06	Merck Patent Gmbh	Monomeric and dimeric antibody-fragment fusion proteins
EP1997894B1 (en)	1992-02-06	2011-03-30	Novartis Vaccines and Diagnostics, Inc.	Biosynthetic binding protein for cancer marker
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US8211422B2 (en)	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
CA2135408A1 (en)	1992-05-08	1993-11-25	Peter C. Keck	Chimeric multivalent protein analogues and methods of use thereof
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
ES2338791T3 (en)	1992-08-21	2010-05-12	Vrije Universiteit Brussel	IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS.
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
EP0672068A4 (en)	1992-09-25	1997-02-26	Commw Scient Ind Res Org	Target binding polypeptide.
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB9221657D0 (en)	1992-10-15	1992-11-25	Scotgen Ltd	Recombinant bispecific antibodies
EP0627932B1 (en)	1992-11-04	2002-05-08	City Of Hope	Antibody construct
GB9323648D0 (en)	1992-11-23	1994-01-05	Zeneca Ltd	Proteins
ES2156149T3 (en)	1992-12-04	2001-06-16	Medical Res Council	MULTIVALENT AND MULTI-SPECIFIC UNION PROTEINS, ITS MANUFACTURE AND USE.
JP3824633B2 (en)	1993-02-12	2006-09-20	ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ	Regulatory transcription of target genes and other biological consequences
US7211259B1 (en)	1993-05-07	2007-05-01	Immunex Corporation	4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6476198B1 (en)	1993-07-13	2002-11-05	The Scripps Research Institute	Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en)	1993-08-13	1997-06-03	The Regents Of The University Of California	Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en)	1993-10-07	1995-04-13	The Regents Of The University Of California	Genetically engineered bispecific tetravalent antibodies
DE69528894T2 (en)	1994-05-02	2003-03-27	Bernd Groner	BIFUNCTIONAL PROTEIN, PRODUCTION AND USE
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
JP3659261B2 (en)	1994-10-20	2005-06-15	モルフォシス・アクチェンゲゼルシャフト	Targeted heterojunction of a recombinant protein to a multifunctional complex
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en)	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
RU2167676C2 (en)	1995-02-24	2001-05-27	Дзе Дженерал Хоспитал Корпорейшн	Redirection of cellular immunity by chimeric receptors
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
DE69633175T2 (en)	1995-05-23	2005-08-11	Morphosys Ag	MULTIMETER PROTEINS
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
WO1997014719A1 (en)	1995-10-16	1997-04-24	Unilever N.V.	A bifunctional or bivalent antibody fragment analogue
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
US5874240A (en)	1996-03-15	1999-02-23	Human Genome Sciences, Inc.	Human 4-1BB receptor splicing variant
US6239259B1 (en)	1996-04-04	2001-05-29	Unilever Patent Holdings B.V.	Multivalent and multispecific antigen-binding protein
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
WO1998006842A1 (en)	1996-08-16	1998-02-19	Schering Corporation	Mammalian cell surface antigens; related reagents
CA2269738A1 (en)	1996-10-25	1998-05-07	Mitchell H. Finer	Targeted cytolysis of cancer cells
JP4187277B2 (en)	1997-04-30	2008-11-26	エンゾンファーマシューティカルズ，インコーポレイテッド	Antigen-binding single chain proteins that can be glycosylated, their production and use
US20030207346A1 (en)	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
EP1012280B1 (en)	1997-06-11	2004-11-10	Borean Pharma A/S	Trimerising module
EP2380906A2 (en)	1997-06-12	2011-10-26	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
US20030060444A1 (en)	1997-06-25	2003-03-27	Celltech Therapeutics, Ltd.	Cell activation process and reagents therefor
GB9713473D0 (en)	1997-06-25	1997-09-03	Celltech Therapeutics Ltd	Biological products
US6509173B1 (en)	1997-10-21	2003-01-21	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
ATE461282T1 (en)	1997-10-27	2010-04-15	Bac Ip Bv	MULTIVALENT ANTIGEN-BINDING PROTEINS
EP1049787B1 (en)	1998-01-23	2004-11-24	Vlaams Interuniversitair Instituut voor Biotechnologie	Multipurpose antibody derivatives
EP1053321A1 (en)	1998-02-09	2000-11-22	Genentech, Inc.	Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CZ121599A3 (en)	1998-04-09	1999-10-13	Aventis Pharma Deutschland Gmbh	Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
DE19819846B4 (en)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalent antibody constructs
GB9809658D0 (en)	1998-05-06	1998-07-01	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
ATE251181T1 (en)	1998-07-28	2003-10-15	Micromet Ag	HETEROMINI BODY
EP1109921A4 (en)	1998-09-04	2002-08-28	Sloan Kettering Inst Cancer	Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en)	1998-10-20	2002-06-25	City Of Hope	CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6333396B1 (en)	1998-10-20	2001-12-25	Enzon, Inc.	Method for targeted delivery of nucleic acids
US7052906B1 (en)	1999-04-16	2006-05-30	Celltech R & D Limited	Synthetic transmembrane components
US7534866B2 (en)	2005-10-19	2009-05-19	Ibc Pharmaceuticals, Inc.	Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en)	2005-10-19	2009-05-05	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
PT1196186E (en)	1999-07-12	2008-02-14	Genentech Inc	Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
BR0013391A (en)	1999-08-17	2002-07-09	Biogen Inc	Use of the baff receptor (bcma) as an immunoregulatory agent
AU1086501A (en)	1999-10-15	2001-04-30	Carnegie Institution Of Washington	Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en)	1999-11-01	1999-12-29	Celltech Therapeutics Ltd	Biological products
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
IL151287A0 (en)	2000-02-24	2003-04-10	Xcyte Therapies Inc	A method for stimulation and concentrating cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
ATE419354T1 (en)	2000-02-25	2009-01-15	Us Gov Health & Human Serv	SCFV MOLECULES AGAINST EGFRVIII WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREOF, AND METHODS OF USE THEREOF
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2895884C (en)	2000-03-06	2019-04-23	University Of Kentucky Research Foundation	A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
DK1267909T3 (en)	2000-03-29	2010-11-08	Univ Ohio State Res Found	Methods for blocking tissue destruction by autoreactive T cells
WO2001077342A1 (en)	2000-04-11	2001-10-18	Genentech, Inc.	Multivalent antibodies and uses therefor
WO2001090192A2 (en)	2000-05-24	2001-11-29	Imclone Systems Incorporated	Bispecific immunoglobulin-like antigen binding proteins and method of production
IL136511A0 (en)	2000-06-01	2001-06-14	Gavish Galilee Bio Appl Ltd	Genetically engineered mhc molecules
WO2001096584A2 (en)	2000-06-12	2001-12-20	Akkadix Corporation	Materials and methods for the control of nematodes
EP1294904A1 (en)	2000-06-30	2003-03-26	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Heterodimeric fusion proteins
ATE545703T1 (en)	2000-07-25	2012-03-15	Immunomedics Inc	MULTIVALENT TARGE-BINDING PROTEIN
GB0025307D0 (en)	2000-10-16	2000-11-29	Celltech Chiroscience Ltd	Biological products
US20040242847A1 (en)	2000-10-20	2004-12-02	Naoshi Fukushima	Degraded agonist antibody
WO2002077029A2 (en)	2000-11-07	2002-10-03	City Of Hope	Cd19-specific redirected immune cells
US7177912B1 (en)	2000-12-22	2007-02-13	Datacore Software Corporation	SCSI transport protocol via TCP/IP using existing network hardware and software
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
AU2002247826A1 (en)	2001-03-13	2002-09-24	University College London	Specific binding members
CN1294148C (en)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	Single-stranded cyctic trispecific antibody
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
AU2002256390B2 (en)	2001-04-30	2007-08-30	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en)	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
ATE477280T1 (en)	2001-06-28	2010-08-15	Domantis Ltd	DOUBLE-SPECIFIC LIGAND AND USE THEREOF
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
WO2003013598A2 (en)	2001-08-09	2003-02-20	Lam Dominic M K	Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
US20050043519A1 (en)	2001-08-10	2005-02-24	Helen Dooley	Antigen binding domains
DE60124912T2 (en)	2001-09-14	2007-06-14	Affimed Therapeutics Ag	Multimeric, single chain, tandem Fv antibodies
US20030148982A1 (en)	2001-11-13	2003-08-07	Brenner Malcolm K.	Bi-spcific chimeric T cells
WO2003049684A2 (en)	2001-12-07	2003-06-19	Centocor, Inc.	Pseudo-antibody constructs
US7638326B2 (en)	2002-01-03	2009-12-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform
AU2003202908A1 (en)	2002-01-03	2003-07-24	The Trustees Of The University Of Pennsylvania	Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003064383A2 (en)	2002-02-01	2003-08-07	Ariad Gene Therapeutics, Inc.	Phosphorus-containing compounds & uses thereof
JP2006502091A (en)	2002-03-01	2006-01-19	イミューノメディクス、インコーポレイテッド	Bispecific antibody point mutations to increase clearance rate
JP4386741B2 (en)	2002-04-15	2009-12-16	中外製薬株式会社	How to create scDb library
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
GB0305702D0 (en)	2003-03-12	2003-04-16	Univ Birmingham	Bispecific antibodies
CA2522819A1 (en)	2003-04-22	2004-11-04	Immunomedics, Inc.	Polyvalent protein complex
KR20060052681A (en)	2003-05-23	2006-05-19	와이어쓰	Gitr ligand and gitr ligand-related molecules and antibody and uses thereof
US20040242504A1 (en)	2003-05-30	2004-12-02	Vadim Ivanov	Novel composition and method for the treatment of hypertension
US7635472B2 (en)	2003-05-31	2009-12-22	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP2322547A1 (en)	2003-06-25	2011-05-18	Crucell Holland B.V.	Myeloid cell-specific lectin
CA2530285C (en)	2003-06-27	2019-12-24	Abgenix, Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005000898A2 (en)	2003-06-27	2005-01-06	Biogen Idec Ma Inc.	Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1638510B1 (en)	2003-07-01	2015-09-02	Immunomedics, Inc.	Multivalent carriers of bi-specific antibodies
US20050048054A1 (en)	2003-07-11	2005-03-03	Shino Hanabuchi	Lymphocytes; methods
US7696322B2 (en)	2003-07-28	2010-04-13	Catalent Pharma Solutions, Inc.	Fusion antibodies
US8198020B2 (en)	2003-08-22	2012-06-12	Potentia Pharmaceuticals, Inc.	Compositions and methods for enhancing phagocytosis or phagocyte activity
CN102060806A (en)	2003-09-11	2011-05-18	iTherX药品公司	Cytokine inhibitors
WO2005029091A2 (en)	2003-09-15	2005-03-31	Oklahoma Medical Research Foundation	Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP1688439A4 (en)	2003-10-08	2007-12-19	Kyowa Hakko Kogyo Kk	Fused protein composition
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) *	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
JP2007518399A (en)	2003-12-02	2007-07-12	ジェンザイムコーポレイション	Compositions and methods for diagnosing and treating lung cancer
JP2007515493A (en)	2003-12-22	2007-06-14	セントカー・インコーポレーテツド	Method for generating multimeric molecules
GB0329825D0 (en)	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
US20050266425A1 (en)	2003-12-31	2005-12-01	Vaccinex, Inc.	Methods for producing and identifying multispecific antibodies
MXPA06008336A (en)	2004-01-23	2007-04-17	Sanofi Pasteur Inc	Cytotoxicity assay.
US8383575B2 (en)	2004-01-30	2013-02-26	Paul Scherrer Institut	(DI)barnase-barstar complexes
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
ES2653570T3 (en)	2004-05-27	2018-02-07	The Trustees Of The University Of Pennsylvania	Innovative artificial antigen presenting cells and uses thereof
WO2006083289A2 (en)	2004-06-04	2006-08-10	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006020258A2 (en)	2004-07-17	2006-02-23	Imclone Systems Incorporated	Novel tetravalent bispecific antibody
CA2577082A1 (en)	2004-09-02	2006-03-16	Genentech, Inc.	Heteromultimeric molecules
US7994298B2 (en)	2004-09-24	2011-08-09	Trustees Of Dartmouth College	Chimeric NK receptor and methods for treating cancer
ES2766123T3 (en)	2004-12-10	2020-06-11	Peter Maccallum Cancer Inst	Methods and compositions for adoptive immunotherapy
RU2436575C2 (en) *	2005-01-21	2011-12-20	Астекс Терапьютикс Лимитед	Compounds used in pharmaceutics
MX2007008781A (en)	2005-01-21	2007-09-11	Astex Therapeutics Ltd	Pharmaceutical compounds.
DK1866339T3 (en)	2005-03-25	2013-09-02	Gitr Inc	GTR-binding molecules and their applications
CN101198698B (en)	2005-03-31	2014-03-19	中外制药株式会社	Process for production of polypeptide by regulation of assembly
CN101484182B (en)	2005-04-06	2014-06-11	Ibc药品公司	Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
EP3479844B1 (en)	2005-04-15	2023-11-22	MacroGenics, Inc.	Covalent diabodies and uses thereof
CA2608474C (en)	2005-05-17	2019-11-12	University Of Connecticut	Compositions and methods for immunomodulation in an organism
US20060263367A1 (en)	2005-05-23	2006-11-23	Fey Georg H	Bispecific antibody devoid of Fc region and method of treatment using same
US20070014720A1 (en)	2005-06-02	2007-01-18	Gadi Gazit-Bornstein	Antibodies directed to CD20 and uses thereof
EP1907424B1 (en)	2005-07-01	2015-07-29	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en)	2005-08-19	2014-08-28	Abbott Lab	Dual variable domain immunoglobin and uses thereof
EP1757622B1 (en)	2005-08-26	2009-12-23	PLS Design GmbH	Bivalent IgY antibody constructs for diagnostic and therapeutic applications
WO2007044887A2 (en)	2005-10-11	2007-04-19	Transtarget, Inc.	Method for producing a population of homogenous tetravalent bispecific antibodies
JP5102772B2 (en)	2005-11-29	2012-12-19	ザ・ユニバーシティ・オブ・シドニー	Demibody: Dimerization activation therapeutic agent
NZ595736A (en)	2005-12-02	2013-05-31	Sinai School Medicine	Chimeric viruses presenting non-native surface proteins and uses thereof
EP1795588A1 (en)	2005-12-07	2007-06-13	Cellerix, S.L.	Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
CA2636111C (en)	2006-01-13	2018-04-03	The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
WO2007133822A1 (en)	2006-01-19	2007-11-22	Genzyme Corporation	Gitr antibodies for the treatment of cancer
BRPI0707824A2 (en)	2006-02-15	2011-05-10	Imclone Systems Inc	antigen-binding protein, and methods of neutralizing tyrosine kinase receptor activation, inhibiting angiogenesis, reducing tumor growth and producing an antigen-binding protein
KR101516823B1 (en)	2006-03-17	2015-05-07	바이오겐 아이덱 엠에이 인코포레이티드	Stabilized polypeptide compositions
WO2007112362A2 (en)	2006-03-24	2007-10-04	The Regents Of The University Of California	Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
SI1999154T1 (en)	2006-03-24	2013-01-31	Merck Patent Gmbh	Engineered heterodimeric protein domains
EP4218801A3 (en)	2006-03-31	2023-08-23	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
EP2799449A1 (en)	2006-05-25	2014-11-05	Bayer Intellectual Property GmbH	Dimeric molecular complexes
US20070274985A1 (en)	2006-05-26	2007-11-29	Stefan Dubel	Antibody
KR101571027B1 (en)	2006-06-12	2015-11-23	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Single-chain multivalent binding proteins with effector function
WO2008022349A2 (en)	2006-08-18	2008-02-21	Armagen Technologies, Inc.	Agents for blood-brain barrier delivery
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
WO2008045437A2 (en)	2006-10-09	2008-04-17	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
ES2870017T3 (en)	2006-11-02	2021-10-26	Biomolecular Holdings Llc	Hybrid polypeptide production methods with moving parts
US20080131415A1 (en)	2006-11-30	2008-06-05	Riddell Stanley R	Adoptive transfer of cd8 + t cell clones derived from central memory cells
WO2008140621A2 (en)	2006-12-21	2008-11-20	Mount Sinai School Of Medicine Of New York University	Transgenic oncolytic viruses and uses thereof
WO2008110491A2 (en)	2007-03-09	2008-09-18	University Of Basel	Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
JP2008228690A (en)	2007-03-23	2008-10-02	Mitsukan Group Honsha:Kk	Protein having sweetness
CN104497143B (en)	2007-03-29	2020-08-25	健玛保	Bispecific antibody and method for producing same
HUE038506T2 (en)	2007-03-30	2018-10-29	Memorial Sloan Kettering Cancer Center	Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8163279B2 (en)	2007-04-13	2012-04-24	Stemline Therapeutics, Inc.	IL3Rα antibody conjugates and uses thereof
CA2682605A1 (en)	2007-04-18	2008-10-30	Zymogenetics, Inc.	Single chain fc, methods of making and methods of treatment
US9931377B2 (en)	2007-06-27	2018-04-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cell expressing complexes of IL-15 and IL-15Ralpha
EP3124046B1 (en)	2007-07-12	2019-12-25	GITR, Inc.	Combination therapies employing gitr binding molecules
AU2008282218A1 (en)	2007-07-31	2009-02-05	Medimmune, Llc	Multispecific epitope binding proteins and uses thereof
EP2532676B1 (en)	2007-08-15	2017-03-22	Bayer Pharma Aktiengesellschaft	Protease-regulated antibody
US20090088373A1 (en)	2007-09-28	2009-04-02	Gallo Richard L	Use of compositions to enhance innate immune response
JP2011504740A (en)	2007-11-27	2011-02-17	アブリンクスエン．ヴェー．	Amino acid sequence directed to heterodimeric cytokines and / or their receptors, and polypeptides containing the same
US20090148905A1 (en)	2007-11-30	2009-06-11	Claire Ashman	Antigen-binding constructs
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US8227577B2 (en)	2007-12-21	2012-07-24	Hoffman-La Roche Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
US10059923B2 (en)	2008-01-30	2018-08-28	Memorial Sloan Kettering Cancer Center	Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
US8379824B2 (en)	2008-03-06	2013-02-19	At&T Intellectual Property I, Lp	Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
US20110177070A1 (en)	2008-07-02	2011-07-21	Emergent Product Development Seatlle, LLC	TGF-Beta Antagonist Multi-Target Binding Proteins
US20110280894A1 (en)	2008-07-31	2011-11-17	Angela Krackhardt	Her2/neu specific t cell receptors
WO2010017317A2 (en)	2008-08-05	2010-02-11	Emory University	Use of mtor inhibitors to enhance t cell immune responses
EP2331566B1 (en)	2008-08-26	2015-10-07	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010030002A1 (en)	2008-09-12	2010-03-18	国立大学法人三重大学	Cell capable of expressing exogenous gitr ligand
CN104042612A (en)	2008-11-11	2014-09-17	得克萨斯大学体系董事会	Inhibition Of Mammalian Target Of Rapamycin
KR20200047793A (en)	2008-12-09	2020-05-07	제넨테크, 인크.	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010083298A1 (en)	2009-01-14	2010-07-22	Health Research Inc.	Methods and compositions containing mtor inhibitors for enhancing immune responses
EP2389443B1 (en)	2009-01-23	2018-11-14	Roger Williams Hospital	Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
ES2550179T3 (en)	2009-02-05	2015-11-05	Icahn School Of Medicine At Mount Sinai	Chimeric Newcastle disease viruses and uses thereof
EP2393835B1 (en)	2009-02-09	2017-04-05	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
SI2406284T1 (en) *	2009-03-10	2017-01-31	Biogen Ma Inc.	Anti-bcma antibodies
EP3505636A1 (en)	2009-04-27	2019-07-03	OncoMed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
ES2598005T3 (en)	2009-08-14	2017-01-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of IL-15 to increase thymus output and to treat lymphopenia
EP2473531A4 (en)	2009-09-03	2013-05-01	Merck Sharp & Dohme	Anti-gitr antibodies
CA2775155A1 (en)	2009-10-01	2011-04-07	Csl Limited	Method of treatment of philadelphia chromosome positive leukemia
US8465743B2 (en)	2009-10-01	2013-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en)	2009-10-29	2015-11-10	The Trustees Of Dartmouth College	T cell receptor-deficient T cell compositions
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
CA2779526C (en)	2009-11-03	2022-12-06	City Of Hope	Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
MX341796B (en)	2009-12-29	2016-09-02	Emergent Product Dev Seattle	Heterodimer binding proteins and uses thereof.
ES2724451T3 (en)	2010-02-04	2019-09-11	Univ Pennsylvania	ICOS fundamentally regulates the expansion and function of inflammatory human Th17 lymphocytes
EA201201435A1 (en)	2010-04-20	2013-04-30	Генмаб А/С	HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
SE535129C2 (en)	2010-07-13	2012-04-24	Bostik Ab	Composition for adhesion of a flooring material
JP6050230B2 (en)	2010-07-21	2016-12-21	サンガモバイオサイエンシーズ，インコーポレイテッド	Methods and compositions for modification of HLA loci
CA2807278A1 (en)	2010-08-24	2012-03-01	F. Hoffmann - La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
US9212229B2 (en)	2010-09-08	2015-12-15	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Chimeric antigen receptors with an optimized hinge region
WO2012033885A1 (en)	2010-09-08	2012-03-15	Baylor College Of Medicine	Immunotherapy of cancer using genetically engineered gd2-specific t cells
EP2632482A4 (en)	2010-10-27	2015-05-27	Baylor College Medicine	Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
EP3974453A3 (en)	2010-11-16	2022-08-03	Amgen Inc.	Agents and methods for treating diseases that correlate with bcma expression
KR101400194B1 (en)	2010-12-01	2014-05-27	제일모직 주식회사	Photosensitive resin composition for color filter, and color filter using the same
SI3214091T1 (en)	2010-12-09	2019-02-28	The Trustees Of The University Of Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
JP5897035B2 (en)	2010-12-14	2016-03-30	ユニバーシティオブメリーランド，ボルチモア	General-purpose anti-tag chimeric antigen receptor-expressing T cells and methods for treating cancer
CN103442768A (en)	2011-01-18	2013-12-11	宾夕法尼亚大学董事会	Compositions and methods for treating cancer
CA2830953C (en)	2011-03-23	2023-02-28	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
WO2012127464A2 (en)	2011-03-23	2012-09-27	Gavish-Galilee Bio Applications Ltd	Constitutively activated t cells for use in adoptive cell therapy
EP3323833B1 (en)	2011-04-01	2019-12-04	Memorial Sloan-Kettering Cancer Center	T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
DK2694640T3 (en)	2011-04-08	2017-11-20	Baylor College Medicine	REVERSION OF THE EFFECTS OF TUMOR MICRO-ENVIRONMENT USING CHEMICAL CYTOKIN RECEPTORS
TR201815488T4 (en)	2011-04-08	2018-11-21	Health	Use of anti-epidermal growth factor receptor variant III for chimeric antigen receptors and cancer treatment.
US20130071414A1 (en)	2011-04-27	2013-03-21	Gianpietro Dotti	Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CA2833820C (en) *	2011-05-27	2019-10-29	Glaxo Group Limited	Bcma (cd269/tnfrsf17) -binding proteins
AU2012286994B2 (en)	2011-07-25	2017-08-10	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of DUX4
JP6334398B2 (en)	2011-07-29	2018-05-30	ザトラスティーズオブザユニバーシティオブペンシルバニア	Switch costimulatory receptors
JP6339015B2 (en)	2011-08-23	2018-06-06	ロシュグリクアートアーゲー	Bispecific T cell activation antigen binding molecule
US20130078250A1 (en)	2011-08-23	2013-03-28	Oliver Ast	Bispecific t cell activating antigen binding molecules
US20130058936A1 (en)	2011-08-23	2013-03-07	Peter Bruenker	Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US9833476B2 (en)	2011-08-31	2017-12-05	The Trustees Of Dartmouth College	NKP30 receptor targeted therapeutics
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
EA201490636A1 (en)	2011-09-16	2014-08-29	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS
WO2013040371A2 (en)	2011-09-16	2013-03-21	Baylor College Of Medicine	Targeting the tumor microenvironment using manipulated nkt cells
CN109485730A (en)	2011-10-20	2019-03-19	美国卫生和人力服务部	Anti- CD22 Chimeric antigen receptor
US9688740B2 (en)	2011-10-26	2017-06-27	National Cancer Center	Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
US10344050B2 (en)	2011-10-27	2019-07-09	Genmab A/S	Production of heterodimeric proteins
WO2013063419A2 (en)	2011-10-28	2013-05-02	The Trustees Of The University Of Pennsylvania	A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US10391126B2 (en)	2011-11-18	2019-08-27	Board Of Regents, The University Of Texas System	CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
CA2859767C (en)	2011-12-19	2018-09-11	Synimmune Gmbh	Bispecific antibody molecule and use thereof for treatment of proliferative disease
WO2013123061A1 (en)	2012-02-13	2013-08-22	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Double transgenic t cells comprising a car and a tcr and their methods of use
US10040846B2 (en)	2012-02-22	2018-08-07	The Trustees Of The University Of Pennsylvania	Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
EP3747898B1 (en)	2012-02-22	2023-03-15	The Trustees of the University of Pennsylvania	Use of icos-based cars to enhance antitumor activity and car persistence
US9783591B2 (en)	2012-02-22	2017-10-10	The Trustees Of The University Of Pennsylvania	Use of the CD2 signaling domain in second-generation chimeric antigen receptors
CA3116051C (en)	2012-03-23	2023-09-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mesothelin chimeric antigen receptors
MX357823B (en) *	2012-04-11	2018-07-25	Us Health	Chimeric antigen receptors targeting b-cell maturation antigen.
ES2924722T3 (en)	2012-05-18	2022-10-10	Aptevo Res & Development Llc	Immunofusion binding of bispecific scFv (BIf) to CD123 and CD3
ES2636902T3 (en)	2012-05-25	2017-10-10	The Regents Of The University Of California	Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
CN103483452B (en)	2012-06-12	2021-08-13	上海细胞治疗集团有限公司	Dual signal independent chimeric antigen receptors and uses thereof
MX2015000426A (en)	2012-07-13	2015-07-14	Univ Pennsylvania	Enhancing activity of car t cells by co-introducing a bispecific antibody.
WO2014011993A2 (en)	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Epitope spreading associated with car t-cells
EA201590207A1 (en)	2012-07-13	2015-05-29	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	COMPOSITIONS AND METHODS OF REGULATION OF CAR-T CELLS
MX2015000438A (en)	2012-07-13	2016-04-25	Univ Pennsylvania	Toxicity management for anti-tumor activity of cars.
KR20210149195A (en)	2012-07-13	2021-12-08	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	Methods of assessing the suitability of transduced T cells for administration
CN104884095A (en)	2012-07-13	2015-09-02	宾夕法尼亚大学董事会	Use of cart19 to deplete normal b cells to induce tolerance
SG11201501259QA (en)	2012-08-20	2015-03-30	Hutchinson Fred Cancer Res	Method and compositions for cellular immunotherapy
US9937205B2 (en)	2012-09-04	2018-04-10	The Trustees Of The University Of Pennsylvania	Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
CN102875685B (en)	2012-09-29	2013-12-25	郑骏年	Chimeric antigen receptor hFVIIL-CD8-OX40-CD3zeta and application thereof
US9365641B2 (en)	2012-10-01	2016-06-14	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
AU2013340799B2 (en)	2012-11-01	2018-08-09	Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc)	An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
WO2014093595A1 (en)	2012-12-12	2014-06-19	The Broad Institute, Inc.	Crispr-cas component systems, methods and compositions for sequence manipulation
CN113355357A (en)	2012-12-12	2021-09-07	布罗德研究所有限公司	Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
US20150368360A1 (en)	2013-02-06	2015-12-24	Anthrogenesis Corporation	Modified t lymphocytes having improved specificity
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
MY190711A (en)	2013-02-20	2022-05-12	Novartis Ag	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
CN103113470B (en)	2013-02-27	2015-04-22	四川大学	Genetically engineered lymphocyte targeting Human EGFR (Epidermal Growth Factor Receptor), preparation method and application of genetically engineered lymphocyte
CN111218429A (en)	2013-03-14	2020-06-02	西奈山伊坎医学院	Newcastle disease virus and uses thereof
US9657105B2 (en)	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
WO2014145252A2 (en)	2013-03-15	2014-09-18	Milone Michael C	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en)	2013-03-16	2019-03-21	諾華公司	Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
WO2014172584A1 (en)	2013-04-17	2014-10-23	Baylor College Of Medicine	IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
CN112795594A (en)	2013-05-14	2021-05-14	得克萨斯州大学系统董事会	Human applications of engineered Chimeric Antigen Receptor (CAR) T cells
WO2014190273A1 (en)	2013-05-24	2014-11-27	Board Of Regents, The University Of Texas System	Chimeric antigen receptor-targeting monoclonal antibodies
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
WO2015090230A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en)	2013-12-20	2015-06-25	Novartis Ag	Regulatable chimeric antigen receptor
WO2015112626A1 (en)	2014-01-21	2015-07-30	June Carl H	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20170335281A1 (en)	2014-03-15	2017-11-23	Novartis Ag	Treatment of cancer using chimeric antigen receptor
EP3119425B1 (en)	2014-03-15	2020-09-23	Novartis AG	Regulatable chimeric antigen receptor
SI3888674T1 (en)	2014-04-07	2024-08-30	Novartis Ag	Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016014501A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase molecules and uses thereof
AU2015292744C1 (en)	2014-07-21	2021-01-21	Novartis Ag	Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
TWI718992B (en)	2014-07-21	2021-02-21	瑞士商諾華公司	Treatment of cancer using a cll-1 chimeric antigen receptor
WO2016014530A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
CN107109419B (en)	2014-07-21	2020-12-22	诺华股份有限公司	Treatment of cancer using CD33 chimeric antigen receptor
EP4205749A1 (en)	2014-07-31	2023-07-05	Novartis AG	Subset-optimized chimeric antigen receptor-containing cells
JP6919118B2 (en)	2014-08-14	2021-08-18	ノバルティスアーゲー	Treatment of cancer with GFRα-4 chimeric antigen receptor
TWI719946B (en)	2014-08-19	2021-03-01	瑞士商諾華公司	Treatment of cancer using a cd123 chimeric antigen receptor
EP3967709A1 (en)	2014-09-17	2022-03-16	Novartis AG	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN114107424A (en)	2014-10-08	2022-03-01	诺华股份有限公司	Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061368A1 (en)	2014-10-15	2016-04-21	The Children's Hospital Of Philadelphia	Compositions and methods for treating b-lymphoid malignancies
CA3197849A1 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
WO2016164580A1 (en)	2015-04-07	2016-10-13	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI746437B (en)	2015-04-08	2021-11-21	瑞士商諾華公司	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
CN118726268A (en)	2015-04-17	2024-10-01	诺华股份有限公司	Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells
US12128069B2 (en)	2015-04-23	2024-10-29	The Trustees Of The University Of Pennsylvania	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016297014B2 (en)	2015-07-21	2021-06-17	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
EP3331913A1 (en)	2015-08-07	2018-06-13	Novartis AG	Treatment of cancer using chimeric cd3 receptor proteins
EP3344996A2 (en)	2015-09-03	2018-07-11	The Trustees Of The University Of Pennsylvania	Biomarkers predictive of cytokine release syndrome
CN108633287A (en)	2015-09-17	2018-10-09	诺华股份有限公司	The CAR T cells treatment of effect enhancing
WO2017112741A1 (en)	2015-12-22	2017-06-29	Novartis Ag	Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
US20190000880A1 (en)	2015-12-30	2019-01-03	Novartis Ag	Immune effector cell therapies with enhanced efficacy
US20190336504A1 (en)	2016-07-15	2019-11-07	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201900677SA (en)	2016-07-28	2019-02-27	Novartis Ag	Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
US20190161542A1 (en)	2016-08-01	2019-05-30	Novartis Ag	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP2019532953A (en)	2016-09-30	2019-11-14	ノバルティスアーゲー	Immune effector cell therapy with enhanced efficacy
CA3039646A1 (en)	2016-10-07	2018-04-12	Novartis Ag	Chimeric antigen receptors for the treatment of cancer
ES2912408T3 (en)	2017-01-26	2022-05-25	Novartis Ag	CD28 compositions and methods for therapy with chimeric receptors for antigens
WO2018144535A1 (en)	2017-01-31	2018-08-09	Novartis Ag	Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en)	2017-02-28	2018-09-07	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20200087376A1 (en)	2017-03-22	2020-03-19	The Trustees Of The University Of Pennsylvania	Biomarkers and car t cell therapies with enhanced efficacy
US20200179511A1 (en)	2017-04-28	2020-06-11	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
SG11202003415XA (en)	2017-10-18	2020-05-28	Novartis Ag	Compositions and methods for selective protein degradation
EP3717907A1 (en)	2017-11-30	2020-10-07	Novartis AG	Bcma-targeting chimeric antigen receptor, and uses thereof
US20200061113A1 (en)	2018-04-12	2020-02-27	Novartis Ag	Chimeric antigen receptor therapy characterization assays and uses thereof
US20200085869A1 (en)	2018-05-16	2020-03-19	Novartis Ag	Therapeutic regimens for chimeric antigen receptor therapies
TW202016139A (en)	2018-06-13	2020-05-01	瑞士商諾華公司	Bcma chimeric antigen receptors and uses thereof

2015
- 2015-07-21 AU AU2015292744A patent/AU2015292744C1/en active Active
- 2015-07-21 WO PCT/US2015/041378 patent/WO2016014565A2/en active Application Filing
- 2015-07-21 BR BR112017001183A patent/BR112017001183A2/en active Search and Examination
- 2015-07-21 KR KR1020177004394A patent/KR102612313B1/en active IP Right Grant
- 2015-07-21 CA CA2955386A patent/CA2955386A1/en active Pending
- 2015-07-21 US US14/805,193 patent/US10174095B2/en active Active
- 2015-07-21 RU RU2017105065A patent/RU2751660C2/en active
- 2015-07-21 EP EP15753519.6A patent/EP3172237A2/en active Pending
- 2015-07-21 SG SG11201700476VA patent/SG11201700476VA/en unknown
- 2015-07-21 MX MX2017001011A patent/MX2017001011A/en unknown
- 2015-07-21 MY MYPI2017700118A patent/MY181834A/en unknown
- 2015-07-21 CN CN201580047918.4A patent/CN106687483B/en active Active
- 2015-07-21 TW TW104123636A patent/TWI750110B/en active
- 2015-07-21 JP JP2017503498A patent/JP7054622B2/en active Active
2017
- 2017-01-10 IL IL250043A patent/IL250043B/en active IP Right Grant
- 2017-01-20 CO CONC2017/0000507A patent/CO2017000507A2/en unknown
2018
- 2018-11-21 US US16/197,565 patent/US11084880B2/en active Active
2020
- 2020-04-23 AU AU2020202726A patent/AU2020202726A1/en not_active Abandoned
- 2020-10-01 JP JP2020167201A patent/JP2021019610A/en active Pending
2021
- 2021-06-25 US US17/359,211 patent/US20220064316A1/en active Pending

Also Published As

Publication number	Publication date
CN106687483A (en)	2017-05-17
US20190153061A1 (en)	2019-05-23
RU2751660C2 (en)	2021-07-15
US10174095B2 (en)	2019-01-08
US20220064316A1 (en)	2022-03-03
CN106687483B (en)	2020-12-04
AU2015292744A1 (en)	2017-02-02
AU2015292744C1 (en)	2021-01-21
AU2015292744B2 (en)	2020-01-30
WO2016014565A2 (en)	2016-01-28
US11084880B2 (en)	2021-08-10
CO2017000507A2 (en)	2017-06-30
TWI750110B (en)	2021-12-21
KR102612313B1 (en)	2023-12-12
BR112017001183A2 (en)	2017-11-28
TW201615832A (en)	2016-05-01
US20160046724A1 (en)	2016-02-18
IL250043B (en)	2021-06-30
EP3172237A2 (en)	2017-05-31
RU2017105065A (en)	2018-08-21
JP2017527271A (en)	2017-09-21
WO2016014565A3 (en)	2016-03-10
IL250043A0 (en)	2017-03-30
MX2017001011A (en)	2018-05-28
KR20170037626A (en)	2017-04-04
JP7054622B2 (en)	2022-04-14
CA2955386A1 (en)	2016-01-28
RU2017105065A3 (en)	2019-02-18
AU2020202726A1 (en)	2020-05-14
AU2015292744A8 (en)	2017-03-09
MY181834A (en)	2021-01-08
JP2021019610A (en)	2021-02-18

Publication	Publication Date	Title
IL280215A (en)	2021-03-01	Treatment of cancer using anti-cd19 chimeric antigen receptor
IL250043B (en)	2021-06-30	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
IL265755A (en)	2019-06-30	Chimeric antigen receptors for the treatment of cancer
IL250116A0 (en)	2017-03-30	Treatment of cancer using a cll-1 chimeric antigen receptor
IL250138A0 (en)	2017-03-30	Treatment of cancer using a cd33 chimeric antigen receptor
IL240335B (en)	2019-10-31	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
IL241261A0 (en)	2015-11-30	Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
IL246540A0 (en)	2016-08-31	Frizzled receptor antibodies for treatment of cancer